

# Overexpression of GSTP1 promotes colorectal cancer cell proliferation, invasion and metastasis by up-regulating STAT3

**Feifei Wang**

Southern Medical University

**Ceng Zhang**

Southern Medical University

**Xiaohui Zhu**

Southern Medical University

**Dan Zhang**

Southern Medical University

**Zhaowen Zhang**

Southern Medical University

**Shunjie Ni**

Southern Medical University

**Zhizhi Wang**

Southern Medical University

**Shuyi Xu**

Southern Medical University

**Xiaoliang Lan**

Southern Medical University

**Yanqing Ding**

Southern Medical University

**Li Liang** (✉ [lli@fimmu.com](mailto:lli@fimmu.com))

Southern Medical University <https://orcid.org/0000-0001-5302-2754>

---

## Research Article

**Keywords:** GSTP1, STAT3, CRC, proliferation, invasion, metastasis

**Posted Date:** March 19th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-315672/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

1 **Overexpression of GSTP1 promotes colorectal cancer cell**  
2 **proliferation, invasion and metastasis by up-regulating STAT3**

3 **Running title: GSTP1 promotes colorectal cancer progression by upregulating**  
4 **STAT3**

5 Feifei Wang<sup>1,2△</sup>, Ceng Zhang<sup>1,2△</sup>, Xiaohui Zhu<sup>1,2△</sup>, Dan Zhang<sup>1,2</sup>, Zhaowen Zhang<sup>1,2</sup>,  
6 Shunjie Ni<sup>3</sup>, Zhizhi Wang<sup>4</sup>, Shuyi Xu<sup>5</sup>, Xiaoliang Lan<sup>6</sup>, Yanqing Ding<sup>1,2</sup>, Li Liang<sup>1,2\*</sup>

7 **Authors' affiliations:**

8 1 Department of Pathology, Nanfang Hospital and Basic Medical College, Southern  
9 Medical University, Guangzhou 510515, Guangdong Province, People's Republic  
10 of China.

11 2 Guangdong Province Key Laboratory of Molecular Tumor Pathology, Guangzhou  
12 510515, Guangdong province, People's Republic of China.

13 3 Department of Neurology, Nanfang Hospital, Southern Medical University,  
14 Guangzhou 510515, Guangdong province, People's Republic of China.

15 4 Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University,  
16 Guangzhou 510515, Guangdong province, People's Republic of China.

17 5 Basic Medical College, Southern Medical University, Guangzhou 510515,  
18 Guangdong Province, People's Republic of China.

19 6 Department of General Surgery, Nanfang Hospital, Southern Medical University,  
20 Guangzhou 510515, Guangdong Province, People's Republic of China.

21 \* **Correspondence to:** Li Liang, Department of Pathology, Nanfang Hospital and  
22 Basic Medical College, Guangdong Province Key Laboratory of Molecular Tumor

23 Pathology, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou  
24 510515, People's Republic of China. Email:lli@fimmu.com. Phone: 86-20-61642148  
25 Fax: 86-20-61648224. ORCID:0000-0001-5302-2754.

26  $\Delta$ : FF Wang, C Zhang and XH Zhu, contributed equally to this work.

## 27 **Abstract**

28 Abnormal expression of glutathione S-transferase Pi 1 (GSTP1) is associated with  
29 the progression of several tumor types. However, its role and molecular mechanism in  
30 the progression of colorectal cancer (CRC) is largely unknown. In the present study,  
31 immunohistochemistry (IHC) and quantitative-reverse transcription PCR (qRT-PCR)  
32 were used to detect the expression of GSTP1 and signal transducer and activator of  
33 transcription 3 (STAT3) in CRC tissues. Western blotting was applied to detect the  
34 expression of GSTP1 and proteins of Janus kinase (JAK)-STAT3 pathway. The  
35 interaction and co-localization of GSTP1 and STAT3 were detected by  
36 co-immunoprecipitation (CO-IP) and immunofluorescence, respectively. A positive  
37 correlation was identified between the expression of GSTP1 and STAT3 in human  
38 CRC tissues. Overexpression of GSTP1 promoted the proliferation, invasion and  
39 metastasis of CRC cells by upregulating STAT3. GSTP1 and STAT3 can directly bind  
40 to and regulate each other, and can be regulated by the upstream gene which was  
41 called F-box only protein 8 (FBX8). The present study demonstrated that GSTP1  
42 could enhance the expression of STAT3 to promote the proliferation, invasion and  
43 metastasis of CRC cells, which provides a potential therapeutic target for clinical  
44 treatment of CRC.

## 45 **Keywords**

46 GSTP1; STAT3, CRC; proliferation; invasion; metastasis

47

## 48 **1. Background**

49 Following the lung and breast cancer, CRC is the third most common cancer  
50 worldwide [1]. The combined application of surgery, chemotherapy and radiotherapy  
51 can control many localized tumors, however, it is limited in the restriction of the  
52 development of metastatic disease [2]. Therefore, further elucidation of the molecular  
53 mechanisms underlying the tumorigenesis and pathogenesis of CRC is urgently  
54 required for this lethal disease.

55 Glutathione S-transferases (GSTs) (EC 2.5.1.18) are phase II metabolic enzymes [3],  
56 which play a role in xenobiotic biotransformation [4], drug metabolism [5], protection  
57 against oxidative stress, and modulating cell proliferation and signaling pathways [6,  
58 7]. The GST Pi 1 (GSTP1), as an isozyme of GST, is a major regulator of cell  
59 signaling in response to stress, hypoxia, growth factors and other stimuli [8]. GSTP1  
60 is overexpressed in a variety of human cancers, including gastric cancer, pancreatic  
61 cancer and bladder cancer [9, 10]. GSTP1 is also involved in the process of  
62 proliferation and invasion in tumor cells; The overexpression of GSTP1 promotes  
63 tumor cell proliferation and inhibits apoptosis in head and neck squamous cell  
64 carcinoma (HNSCC) [11]. However, GSTP1 inhibits the proliferation of bladder  
65 cancer T24 cells and arrests these cells in the G0/G1 phase [12]. In addition, a recent  
66 study suggested that GSTP1 may be applied as an important biomarker for liquid

67 biopsy [13].

68 The signal transducer and activator of transcription (STAT) family is phosphorylated  
69 via Janus kinases (JAKs) in response to the binding of growth factors or cytokines to  
70 their corresponding receptors [14-16]. These factors are known to stimulate the  
71 activation of intracellular STAT proteins, which are phosphorylated and dimerized,  
72 and subsequently translocated to the nucleus for transactivation of a number of genes  
73 involved in numerous cellular processes [17]. Persistent activation of STAT3 has been  
74 observed in multiple human malignancies, including various stages of CRC [18-20].  
75 Furthermore, high expression of STAT3 alters the cell cycle [21, 22] and inhibits  
76 apoptosis by upregulating anti-apoptotic signaling [23, 24] in inflammation-associated  
77 CRC and other human cancers [25]. In addition, GSTP1 negatively regulates STAT3  
78 activation in epidermal growth factor (EGF) signaling, and is also a regulator of the  
79 cell cycle via EGF signaling in human hepatocellular carcinoma (HCC) [8]. However,  
80 the regulatory mechanisms between GSTP1 and STAT3 in the progression of CRC  
81 remain unknown.

82 In our previous studies, it was identified that the loss of F-box only protein 8  
83 (FBX8) in hepatocellular carcinoma, gastric cancer and CRC was associated with  
84 poor survival of patients [26-28]. FBX8 is a metastatic suppressor downstream of  
85 miR-223 and targets mTOR degradation in CRC [27]. It was also found that FBX8  
86 inhibits the proliferation, invasion and metastasis of CRC by promoting the  
87 degradation of GSTP1. At the same time, it was confirmed that GSTP1 can be used as  
88 an effective marker to predict the prognosis of CRC [29].

89 The present study revealed that overexpression of GSTP1 can promote the  
90 proliferation, invasion and metastasis of CRC cells by upregulating STAT3, and this  
91 function can be regulated by FBX8. Therefore, it may provide a potential therapeutic  
92 target for the clinical treatment of CRC.

93

## 94 **2. Materials and methods**

### 95 *2.1 IHC*

96 The sections were dewaxed and rehydrated, the endogenous peroxidase was  
97 eliminated with 3% H<sub>2</sub>O<sub>2</sub>. The antigen was repaired with 0.01 M, pH 6.0 sodium  
98 citrate buffer by microwave oven boiling for 5 min. After blocking with 5% goat  
99 serum at room temperature for 1 h, add anti-GSTP1(1:200) or anti-STAT3(1:100)  
100 antibody which were diluted with appropriate proportion about 50 µl and overnight at  
101 4°C. Incubating with horseradish egg protein rabbit secondary antibody or murine  
102 secondary antibody for 90 min at room temperature. Labeling streptavidin with  
103 appropriate horseradish peroxidase, incubate for 30 min at room temperature. DAB  
104 color developer needs to be observed under the microscope.

105 Staining was scored in a double-blind manner by two individuals with a score of 0  
106 (representative negative), 1 (weak), 2 (medium), and 3 (strong). Depending on the  
107 percentage of the stained area relative to the total cancerous tissue area or blood  
108 vessel, the staining range is divided into 0 points (0%), 1 point (1-25%), 2 points  
109 (26-50%), 3 points (51-75%) and 4 points (76 -100%). the sum of the dyeing strength  
110 and range was taken as the final dyeing value (0-7): (-) total score <3 points, (+) total

111 score 3 points, (++) total score 4 points, (+++) total score is 5 points or more, in  
112 which - or + is a low expression group, ++ and +++ are high expression groups.

### 113 *2.2 Immunofluorescence*

114 For immunofluorescence of cells seeded at a density of  $0.5 \times 10^4$  cells on Confocal  
115 NEST dish glass bottom Petri dishes. After 24 h, cells were fixed in 4%  
116 paraformaldehyde, permeabilized with 0.02% Triton-X/1 × PBS, and blocked in 1 ×  
117 PBS + 10% fetal bovine serum and 1% BSA. Primary GSTP1 (1:200) and STAT3  
118 (1:100) antibodies were incubated overnight at 4°C at the dilutions listed below in 1 ×  
119 PBS. Secondary antibodies coupled to Alexa Fluor 488 or 594 (Invitrogen) was  
120 incubated 2 h at room temperature. Nuclear DNA was stained with 4',  
121 6-diamidino-2-phenylindole (DAPI). Confocal images were taken by Olympus  
122 inverted fluorescence microscope and were outputted by PV10-ASW 1.7 viewer  
123 software.

### 124 *2.3 Co-IP*

125 In brief, the extracts of SW620 cells were blocked with IgG or protein A/G-agarose  
126 2 h at 4°C to get rid of unspecific protein binding and then they were incubated with  
127 anti-FBX8 or anti-GSTP1 antibody overnight at 4°C. The protein A/G-agarose was  
128 separated out by centrifugation at 4°C, 2500 rpm. PVDF membranes were blocked  
129 with 5% skim milk 1 h at room temperature and incubated with GSTP1 (1:200) and  
130 STAT3 (1:100) antibodies overnight at 4°C at the dilutions listed below in 5% skim  
131 milk. Protein bands were visualized using enhanced chemiluminescence kit HRP (FD  
132 bio-femto ECL Kit).



133 *2.4 Glutathione S-transferase (GST) pull-down assay*

134 The interaction of truncated GSTP1 with STAT3 was examined in HCT116 and  
135 SW620 cells by GST-mediated pull-down assays (Thermo Scientific, Rockford, IL).  
136 Recombinant GST-STAT3-CCD (218-400), GST-STAT3-DBD (401-564),  
137 GST-STAT3-Linker (565-663) and GST-STAT3-SH2 (664-768) proteins were  
138 expressed and purified. Purified GST-STAT3-CCD (218-400), GST-STAT3-DBD  
139 (401-564), GST-STAT3-Linker (565-663) and GST-STAT3-SH2 (664-768) fragments  
140 were bound to glutathione resin as a GST-fusion protein and incubated with GSTP1 at  
141 4°C for 2 h. After extensive washing with assay buffer, the complex was eluted with 5  
142 mM reduced glutathione and the bound protein complexes were disrupted. Then, the  
143 proteins were separated on SDS-PAGE and Western blotting.

144 *2.5 Statistical analysis*

145 All statistical analyses were performed by SPSS version 22.0 (IBM, USA). The  
146 results were presented as mean  $\pm$  SD. Pearson correlation analysis was applied to  
147 analyze the correlation between GSTP1 and STAT3. For experiments among/between  
148 sample groups or three comparisons were analyzed by one-way ANOVA or  
149 independent samples T-test. Before the analysis of variance, Levene test was used for  
150 variance. A two-tailed  $P < 0.05$  was considered as statistically significant in all tests.

151 Detailed methods about Plasmids and siRNA transfection, Cell proliferation  
152 assay(CCK8), Cell invasion assays in vitro, Western blotting, qRT-PCR analysis were  
153 described in Appendix A–Supplementary data.

154

155 **3. Results**

156 **3.1 The expression levels of GSTP1 and STAT3 are positively correlated**  
157 **in human CRC tissues**

158 STAT3, widely recognized as a cancer gene, is typically associated with poor  
159 prognosis of various human malignancies and promotes cancer progression or  
160 metastasis [30-33]. The direct interaction between GSTP1 and STAT3 can promote  
161 HCC progression [8], and our previous study found that GSTP1 can be ubiquitinated  
162 by FBX8, thus inhibiting its function in promoting CRC proliferation, invasion and  
163 metastasis [29]. Therefore, IHC was used to detect the expression of GSTP1 and  
164 STAT3 in 20 human CRC tissues. The results demonstrated that the expression levels  
165 of GSTP1 and STAT3 in human CRC tissues were positively correlated (Figure 1A).  
166 Western blotting and qRT-PCR were used to detect the expression levels of GSTP1  
167 and STAT3 in 8 paired fresh CRC tissues (Figure 1B and 1C). As shown in (Figure  
168 1D), the expression of GSTP1 was also positively correlated with STAT3 in paired  
169 fresh CRC tissues (Pearson's  $r = -0.8781$ ,  $P = 0.0006$ ).

170

171 **3.2 Overexpression of GSTP1 promotes the proliferation, invasion and**  
172 **metastasis of CRC cells dependent on STAT3**

173 The expression of GSTP1 is positively correlated with STAT3. Combined with  
174 previous studies, we predicted GSTP1 may play a role in the progression of CRC by  
175 regulating STAT3. CRC cell lines with stable knockdown of GSTP1 were used in the  
176 previous study [29] (SW620/shGSTP1 and HCT116/shGSTP1 cell lines), and STAT3

177 was overexpressed in these cells to perform relevant recovery experiments. As shown  
178 in (Figure 2A and 2B), overexpression of STAT3 could significantly promote the  
179 invasion and proliferation of cells in the GSTP1-knockdown group in vitro. In  
180 addition, the expression levels of STAT3 and GSTP1 were detected in subcutaneous  
181 tumors, in situ implants and liver metastases of CRC in nude mice, which were  
182 obtained from a previous study. The results demonstrated that in these three tumor  
183 tissues, the expression of STAT3 was significantly upregulated in the GSTP1  
184 overexpressed group (Figure 3A and 3B), which indicated that the expression of  
185 GSTP1 and STAT3 in mice tissue samples are consistent.

186

### 187 3.3 GSTP1 and STAT3 can directly bind and regulate each other

188 It was further hypothesized that GSTP1 could interact with STAT3 in CRC cells. As  
189 expected, Co-IP analyses and immunofluorescence identified the interaction between  
190 the two proteins. The existence of GSTP1 was detected in the immunoprecipitates  
191 obtained with an antibody against STAT3 (Figure 4A). Immunofluorescence  
192 demonstrated that GSTP1 and STAT3 exhibited co-localization in the cytoplasm of  
193 SW620 cells (Figure 4B). The present study cloned four truncated constructs of  
194 STAT3: CCD (218-400), DBD (401-564), Linker (565-663) and SH2 (664-768)  
195 (Figure 4C), and then identified an interaction between the CCD domain of STAT3  
196 and GSTP1 by GST pull-down (Figure 4C). It was identified that the CCD domain of  
197 STAT3 was essential for the interaction with GSTP1.

198 Thus, it was examined whether GSTP1 could activate the STAT3 signaling pathway

199 in CRC cells, and it was identified that exogenous expression of GSTP1 further  
200 increased the protein expression of phosphorylated (p)-STAT3, STAT3 and the  
201 downstream STAT3 targets cyclin D1 and CDC25A in SW480 cells (Figure 4D).  
202 However, there was no appreciable effect on the upstream components of the STAT3  
203 signaling pathway, such as JAK2 and p-JAK2 (Figure 4D). By contrast, depletion of  
204 GSTP1 in SW620 cells decreased the levels of p-STAT3, STAT3, cyclin D1, and  
205 CDC25A (Figure 4D). Notably, this regulation was not one-way; it was identified that  
206 ectopic expression of STAT3 could also upregulate the protein level of GSTP1 and  
207 induce higher levels of the downstream STAT3 targets cyclin D1 and CDC25A. At the  
208 same time, silencing STAT3 could decrease the expression levels of GSTP1, cyclin  
209 D1 and CDC25A, but not the expression of p-JAK2 (Figure 4E). In addition, when  
210 AG490 (100  $\mu$ M) was used to block the JAK2-STAT3 pathway, a significant decrease  
211 was observed in the expression of JAK2, p-JAK2, STAT3, p-STAT3 and GSTP1 24 h  
212 after treating LoVo cells (Figure 4F).

213

### 214 3.4 The interaction between GSTP1 and STAT3 is regulated by FBX8

215 As a downstream target of FBX8, GSTP1 can interact with STAT3, therefore, we  
216 predicted that FBX8 could regulate the interaction between GSTP1 and STAT3. Co-IP  
217 assays demonstrated that the existence of GSTP1, in FBX8-expressing SW620 and  
218 SW480/FBX8 cells, was detected to a higher extent in the immunoprecipitates  
219 obtained with an antibody against STAT3 compared with the control cells (Figure 5A  
220 and 5B). However, the presence of GSTP1 demonstrated the opposite results; it was

221 detected to a lesser extent in the immunoprecipitates obtained with an antibody  
222 against STAT3 (Figure 5A and 5B). These results indicated that FBX8 was a  
223 suppressive factor for the combination of GSTP1 and STAT3.

224

## 225 **4. Discussion**

226 Previously, we identified GSTP1 as the downstream target of FBX8 by Co-IP and  
227 mass spectrometry analyses, and confirmed that GSTP1 can promote the proliferation,  
228 invasion and metastasis of CRC [29]. In addition, it was identified that GSTP1 could  
229 regulate STAT3 to affect the development of HCC [8]. Therefore, we hypothesized  
230 that GSTP1 may be involved in the progression of CRC by regulating STAT3.

231 The present study detected GSTP1 and STAT3 in human colorectal tissues and found  
232 that GSTP1 expression was positively correlated with STAT3 expression. This result  
233 revealed that GSTP1 may be able to regulate the expression of STAT3 to play a role in  
234 the progression of CRC. Recent evidence suggests GSTP1 is involved in tumor cell  
235 proliferation and invasion; overexpression of GSTP1 increased cell proliferation in  
236 HNSCC [11]. In comparison, GSTP1 arrests bladder cancer T24 cells in the G0/G1  
237 phase and upregulates p21 expression [12]. The present study investigated the effect  
238 of GSTP1 on the proliferation and invasion of CRC cells in vitro by recovery  
239 experiments. The results demonstrated that overexpression of STAT3 could  
240 significantly promote the proliferation and invasion of CRC cells after GSTP1  
241 downregulation. This indicated that GSTP1 promoted the proliferation and invasion  
242 of CRC cells depending on STAT3. In addition, the immunohistochemical results of

243 subcutaneous tumors, *in situ* implanted tumors and liver metastases of CRC in mice  
244 also confirmed the aforementioned conclusion.

245 Mechanistically, the present studies served as a proof-of-concept that GSTP1 and  
246 STAT3 can form a complex, and that upregulation of GSTP1 led to activation of the  
247 STAT3 pathway (Figure 6). Meanwhile, STAT3 can positively regulate the protein  
248 expression of GSTP1. STAT3 is phosphorylated via JAK, then dimerized and  
249 subsequently translocated to the nucleus for transactivation of a number of genes  
250 involved in numerous cellular processes [14-17]. In addition, the overexpression of  
251 STAT3 can affect the cell cycle [21, 22] or inhibit apoptosis by enhancing  
252 anti-apoptotic signaling [23, 24] in CRC. Therefore, identifying the association  
253 between GSTP1 and the STAT3 pathway is an important way to illustrate the  
254 molecular mechanisms of GSTP1 in CRC. The present results confirmed the  
255 interaction of GSTP1 and STAT3, and demonstrated that GSTP1 positively regulated  
256 STAT3 signaling, resulting in the alteration of p-STAT3 and STAT3, as well as the  
257 targeted genes such as cyclin D1 and CDC25A. STAT3 siRNA significantly abolished  
258 the increase of STAT3, cyclin D1 and CDC25A, and decreased the protein expression  
259 of GSTP1, but there was no change in p-JAK2. Exogenous STAT3 exhibited the  
260 adverse results. In addition, western blotting revealed a concentration-dependent  
261 decrease in the level of JAK2, p-JAK2, STAT3, p-STAT3 and GSTP1 after 24 h of  
262 treating LoVo cells with the specific inhibitor (AG490) of JAK2. These results  
263 demonstrated GSTP1 interacted with STAT3 without involvement of JAK2.  
264 Combined with previous research that FBX8 can degrade the expression of GSTP1

265 [29], we speculated that FBX8 could affect the association of GSTP1 and STAT3.  
266 Subsequent experiments confirmed that FBX8 was a restraining factor for the  
267 combination of GSTP1 and STAT3.

268

## 269 **5. Conclusions**

270 In summary, GSTP1, as the downstream effector of FBX8, was identified as an  
271 important promoter and a useful prognostic marker for CRC. GSTP1 could interact  
272 with STAT3 and upregulate the expression of STAT3, as well as its related  
273 downstream molecules [34], to promote the proliferation, invasion and metastasis of  
274 CRC. Therefore, the present study provided a potential new molecular target for the  
275 treatment of CRC metastasis.

276

## 277 **List of abbreviations**

278 GSTP1      glutathione S-transferase Pi 1  
279 CRC        colorectal cancer  
280 STAT3      signal transducer and activator of transcription 3  
281 FBX8      F-box only protein 8  
282 IHC        immunohistochemistry  
283 qRT-PCR    reverse transcription-quantitative PCR  
284 CO-IP      co-immunoprecipitation

285

## 286 **Declaration of ethics approval and consent to participate**

287 Fresh CRC tissues were obtained from the department of pathology in nanfang  
288 hospital, and prior approval was obtained from the Southern Medical University  
289 Institutional Board (Guangzhou, China). Informed consent was obtained from each  
290 patient. Animal studies were reviewed and approved by the Institutional Animal Care  
291 and Use Committee of Southern Medical University.

292

### 293 **Declaration of availability of data and materials**

294 All data and models generated or used during the study appear in the submitted  
295 article.

296

### 297 **Declaration of competing interests**

298 The authors declare that they have no competing interests.

299

### 300 **Funding**

301 This work was supported by the National Key R&D program of China (Grant  
302 No.2017YFC1309002); National Natural Science Foundation of China (Grant  
303 No.81672821; No.81872041; No.81802306; No.81903002); Project funded by China  
304 Postdoctoral Science Foundation (Grant No.2018M643125; No.2019M652963);  
305 Natural Science Foundation Key program of Guangdong Province of china (Grant  
306 No.2018B0303110017); Natural Science Foundation of Guangdong Province of china  
307 (Grant No.2019A1515011436).

308



309 **Authors' contributions**

310 Feifei Wang, Ceng Zhang, Xiaohui Zhu and Dan Zhang: Experiments. Shunjie Ni,  
311 Zhizhi Wang and Professor Yanqing Ding: Statistical analysis. Zhaowen Zhang, Shuyi  
312 Xu and Xiaoliang Lan: Collecting tissue samples. Professor Li Liang: Conceived  
313 experiments. Analyzed data. Feifei Wang, Xiaohui Zhu and Li Liang: Writing the  
314 paper. All authors read and approved the final manuscript.

315

316 **References**

- 317 [1] Parkin DM. Global cancer statistics in the year 2000. *The Lancet Oncology*.  
318 2001; 2:533-543. [https://doi.org/10.1016/s1470-2045\(01\)00486-7](https://doi.org/10.1016/s1470-2045(01)00486-7).
- 319 [2] Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. *Nature*  
320 *medicine*. 2006; 12:895-904. <https://doi.org/10.1038/nm1469>.
- 321 [3] Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, et al.  
322 FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell  
323 lymphomas. *Nature*. 2012; 481:90-93. <https://doi.org/10.1038/nature10688>.
- 324 [4] Jakoby WB. The glutathione S-transferases: a group of multifunctional  
325 detoxification proteins. *Advances in enzymology and related areas of molecular*  
326 *biology*. 1978; 46:383-414. <https://doi.org/10.1002/9780470122914.ch6>.
- 327 [5] Chasseaud LF. The role of glutathione and glutathione S-transferases in the  
328 metabolism of chemical carcinogens and other electrophilic agents. *Advances in*  
329 *cancer research*. 1979; 29:175-274. [https://doi.org/10.1016/s0065-230x\(08\)60848-9](https://doi.org/10.1016/s0065-230x(08)60848-9).
- 330 [6] Eaton DL, Bammler TK. Concise review of the glutathione S-transferases and  
331 their significance to toxicology. *Toxicological sciences : an official journal of the*  
332 *Society of Toxicology*. 1999; 49:156-164. <https://doi.org/10.1093/toxsci/49.2.156>.
- 333 [7] Townsend D, Tew K. Cancer drugs, genetic variation and the  
334 glutathione-S-transferase gene family. *American journal of pharmacogenomics :  
335 genomics-related research in drug development and clinical practice*. 2003;

336 3:157-172.<https://doi.org/10.2165/00129785-200303030-00002>.

337 [8] Kou X, Chen N, Feng Z, Luo L, Yin Z. GSTP1 negatively regulates Stat3  
338 activation in epidermal growth factor signaling. *Oncology letters*. 5:1053-1057.  
339 <https://doi.org/10.3892/ol.2012.1098>.

340 [9] Howells RE, Dhar KK, Hoban PR, Jones PW, Fryer AA, Redman CW, et al.  
341 Association between glutathione-S-transferase GSTP1 genotypes, GSTP1  
342 over-expression, and outcome in epithelial ovarian cancer. *International journal of*  
343 *gynecological cancer : official journal of the International Gynecological Cancer*  
344 *Society*. 2004; 14:242-250.<https://doi.org/10.1111/j.1048-891X.2004.014207.x>.

345 [10] Ruzza P, Rosato A, Rossi CR, Floreani M, Quintieri L. Glutathione transferases  
346 as targets for cancer therapy. *Anti-cancer agents in medicinal chemistry*. 2009;  
347 9:763-777. <https://doi.org/10.2174/187152009789056895>.

348 [11] Mutallip M, Nohata N, Hanazawa T, Kikkawa N, Horiguchi S, Fujimura L, et  
349 al. Glutathione S-transferase P1 (GSTP1) suppresses cell apoptosis and its regulation  
350 by miR-133 $\alpha$  in head and neck squamous cell carcinoma (HNSCC). *International*  
351 *journal of molecular medicine*. 2011; 27:345-352.  
352 <https://doi.org/10.3892/ijmm.2010.589>.

353 [12] Gao L, Fang YQ, Zhang TY, Ge B, Xu B, Huang JF, et al. GSTP1 arrests  
354 bladder cancer T24 cells in G0/G1 phase and up-regulates p21 expression.  
355 *International journal of clinical and experimental medicine*. 2014; 7:2984-2991.

356 [13] Gurioli G, Martignano F, Salvi S, Costantini M, Gunelli R, Casadio V. GSTP1  
357 methylation in cancer: a liquid biopsy biomarker? *Clinical chemistry and laboratory*  
358 *medicine*. 2018; 56:702-717.<https://doi.org/10.1515/cclm-2017-0703>.

359 [14] Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors  
360 provides novel molecular targets for therapeutic intervention. *Clinical cancer research :*  
361 *an official journal of the American Association for Cancer Research*. 2002;8:945-954.

362 [15] Quintás-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway:  
363 mutations, inhibitors, and resistance. *Clinical cancer research : an official journal of*  
364 *the American Association for Cancer Research*.

365 2013;19:1933-1940.<https://doi.org/10.1515/cclm-2017-0703>.

366 [16] Yu CL, Meyer DJ, Campbell GS, Lerner AC, Carter-Su C, Schwartz J, et al.  
367 Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the  
368 Src oncoprotein. Science (New York, NY). 1995;  
369 269:81-83.<https://doi.org/10.1126/science.7541555>.

370 [17] Takeda K, Akira S. STAT family of transcription factors in cytokine-mediated  
371 biological responses. Cytokine & growth factor reviews. 2000;  
372 11:199-207.[https://doi.org/10.1016/s1359-6101\(00\)00005-8](https://doi.org/10.1016/s1359-6101(00)00005-8).

373 [18] Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al.  
374 Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell  
375 carcinogenesis in vivo. Proceedings of the National Academy of Sciences of the  
376 United States of America. 2000;97:4227-4232.<https://doi.org/10.1073/pnas.97.8.4227>.

377 [19] Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3  
378 oncogene product in human ovarian carcinoma cells. Gynecologic oncology. 2000;  
379 79:67-73.<https://doi.org/10.1006/gyno.2000.5931>.

380 [20] Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ.  
381 Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis  
382 in glioblastoma multiforme cells. Oncogene. 2002;  
383 21:8404-8413.<https://doi.org/10.1038/sj.onc.1206047>.

384 [21] Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, et al.  
385 Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines:  
386 inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon  
387 carcinoma cells. The American journal of pathology. 2005; 167:969-980.  
388 [https://doi.org/10.1016/s0002-9440\(10\)61187-x](https://doi.org/10.1016/s0002-9440(10)61187-x).

389 [22] Yu LZ, Wang HY, Yang SP, Yuan ZP, Xu FY, Sun C, et al. Expression of  
390 interleukin-22/STAT3 signaling pathway in ulcerative colitis and related  
391 carcinogenesis. World journal of gastroenterology. 2013; 19:2638-2649.  
392 <https://doi.org/10.3748/wjg.v19.i17.2638>.

393 [23] Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, et al.  
394 Persistent STAT3 activation in colon cancer is associated with enhanced cell

395 proliferation and tumor growth. *Neoplasia* (New York, NY). 2005; 7:545-555.  
396 <https://doi.org/10.1593/neo.04571>.

397 [24] Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al.  
398 Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in  
399 growth regulation of human breast carcinoma cells. *Oncogene*. 2001; 20:2499-2513.  
400 <https://doi.org/10.1038/sj.onc.1204349>.

401 [25] Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a  
402 leading role for STAT3. *Nature reviews Cancer*. 2009; 9:798-809.  
403 <https://doi.org/10.1038/nrc2734>.

404 [26] Wang F, Qiao Y, Yu J, Ren X, Wang J, Ding Y, et al. FBX8 Acts as an Invasion  
405 and Metastasis Suppressor and Correlates with Poor Survival in Hepatocellular  
406 Carcinoma. *PloS one*. 2013; 8:e65495.<https://doi.org/10.1371/journal.pone.0065495>.

407 [27] Wang FF, Zhang XJ, Yan YR, Zhu XH, Yu J, Ding Y, et al. FBX8 is a  
408 metastasis suppressor downstream of miR-223 and targeting mTOR for degradation in  
409 colorectal carcinoma. *Cancer letters*. 2017; 388:85-95.  
410 <https://doi.org/10.1016/j.canlet.2016.11.031>.

411 [28] Wu P, Wang F, Wang Y, Men H, Zhu X, He G, et al. Significance of FBX8 in  
412 progression of gastric cancer. *Experimental and molecular pathology*. 2015;  
413 98:360-366.<https://doi.org/10.1016/j.yexmp.2015.03.015>.

414 [29] FeiFei W, HongHai X, YongRong Y, PingXiang W, JianHua W, XiaoHui Z, et  
415 al. FBX8 degrades GSTP1 through ubiquitination to suppress colorectal cancer  
416 progression. *Cell death & disease*. 2019; 10:351.  
417 <https://doi.org/10.1038/s41419-019-1588-z>.

418 [30] Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation  
419 of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of  
420 incidence and its association with pathological features and clinical outcome. *The*  
421 *Journal of urology*. 2002;168:762-765.

422 [31] Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al.  
423 Constitutive activation of signal transducers and activators of transcription 3  
424 correlates with cyclin D1 overexpression and may provide a novel prognostic marker

425 in head and neck squamous cell carcinoma. *Cancer research*. 2002; 62:3351-3355.

426 [32] Kawada M, Seno H, Uenoyama Y, Sawabu T, Kanda N, Fukui H, et al. Signal  
427 transducers and activators of transcription 3 activation is involved in nuclear  
428 accumulation of beta-catenin in colorectal cancer. *Cancer research*. 2006;  
429 66:2913-2917.<https://doi.org/10.1158/0008-5472.can-05-3460>.

430 [33] Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, et al.  
431 STAT3 expression, molecular features, inflammation patterns, and prognosis in a  
432 database of 724 colorectal cancers. *Clinical cancer research : an official journal of the*  
433 *American Association for Cancer Research*. 2011; 17:1452-1462.  
434 <https://doi.org/10.1158/1078-0432.ccr-10-2694>.

435 [34] Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors:  
436 emerging opportunities and challenges. *Oncogene*. 2016; 35:939-951.  
437 <https://doi.org/10.1038/onc.2015.150>.

438

439 **Figure 1. GSTP1 expression is positively correlated with the expression of STAT3**  
440 **in human colorectal cancer tissues**

441 (A) The expression levels of GSTP1 and STAT3 in human CRC tissues were detected  
442 by IHC. Scale bars represent 50  $\mu\text{m}$  (left) and 20  $\mu\text{m}$  (right). (B) Western blot analysis  
443 was performed to detect the expression levels of GSTP1 and STAT3 in 8 paired fresh  
444 tissue samples of human CRC. (C) The relative mRNA expression levels of GSTP1  
445 and STAT3 in 8 paired fresh tissue samples of human CRC were detected by  
446 qRT-PCR. All samples were tested in triplicate. Bars represent the mean  $\pm$  SD. (D)  
447 The correlation analysis between GSTP1 and STAT3 was performed by Pearson's  
448 correlation analysis (Pearson's  $r = -0.8781$ ,  $P = 0.0006$ ).

449 **Figure 2. Overexpression of STAT3 can reverse the inhibition of invasion and**  
450 **proliferation induced by downregulating GSTP1**

451 (A) Effects of overexpression of STAT3 on SW620/shGSTP1 and HCT116/shGSTP1  
452 cell invasion were detected by invasion assay. Scale bars represent 50  $\mu$ m. All samples  
453 were analyzed in triplicate. Bars represent the mean  $\pm$  SD. \*P<0.05, \*\*P<0.01. (B)  
454 Effects of overexpression of STAT3 on SW620/shGSTP1 and HCT116/shGSTP1 cell  
455 proliferation were detected by CCK8 assay. All samples were tested in triplicate. Bars  
456 represent the mean  $\pm$  SD. \*P<0.05, \*\*P<0.01.

457 **Figure 3. Overexpression of GSTP1 can upregulate the expression of STAT3 in**  
458 **vivo**

459 (A) The expressions of GSTP1 and STAT3 in subcutaneous tumors of nude mice were  
460 detected by immunohistochemistry. Scale bars represent 50  $\mu$ m (left) and 20  $\mu$ m  
461 (right). (B) The expression of GSTP1 and STAT3 in orthotopic implantation of  
462 colorectal tumors and liver metastases in nude mice were detected by  
463 immunohistochemistry. Scale bars represent 50  $\mu$ m (left) and 20  $\mu$ m (right).

464 **Figure 4. GSTP1 and STAT3 can interact with each other**

465 (A) The interaction between GSTP1 and STAT3 was detected by a  
466 co-immunoprecipitation assay with the SW620 cell line. (B) The co-location between  
467 GSTP1 and STAT3 was detected by an immunofluorescence assay with the SW620  
468 cell line. Scale bars represent 10  $\mu$ m. (C) The direct interaction site between GSTP1  
469 and STAT3 was detected by a GST pull-down assay. (D) Western blot analysis was  
470 performed to detect the expression of JAK/STAT3 signaling pathway-related proteins  
471 in SW620/siGSTP1 and SW480/GSTP1 cell lines. (E) Western blot analysis was  
472 performed to detect the expression of JAK/STAT3 signaling pathway-related proteins

473 in SW620/siSTAT3 and LoVo/STAT3 cell lines. **(F)** Western blot analysis was  
474 performed to detect the expression of GSTP1 and JAK/STAT3 signaling  
475 pathway-related proteins following AG490 treatment of LoVo cells.


476 **Figure 5. The interaction between GSTP1 and STAT3 is regulated by FBX8**

477 **(A)** The interaction between GSTP1 and STAT3 was detected by a CO-IP assay after  
478 AG490 treatment of SW620 cells. **(B)** The interaction between GSTP1 and STAT3  
479 was detected by a CO-IP assay with SW480/FBX8 cells.

480 **Figure 6. Schematic diagram of the role between GSTP1 and STAT3 in CRC**




# Figures



**Figure 1**


GSTP1 expression is positively correlated with the expression of STAT3 in human colorectal cancer tissues (A) The expression levels of GSTP1 and STAT3 in human CRC tissues were detected by IHC. Scale bars represent 50  $\mu\text{m}$  (left) and 20  $\mu\text{m}$  (right). (B) Western blot analysis was performed to detect the expression levels of GSTP1 and STAT3 in 8 paired fresh tissue samples of human CRC. (C) The relative mRNA expression levels of GSTP1 and STAT3 in 8 paired fresh tissue samples of human CRC were detected by qRT-PCR. All samples were tested in triplicate. Bars represent the mean  $\pm$  SD. (D) The correlation analysis between GSTP1 and STAT3 was performed by Pearson's correlation analysis (Pearson's  $r = -0.8781$ ,  $P = 0.0006$ ).





**Figure 2**


Overexpression of STAT3 can reverse the inhibition of invasion and proliferation induced by downregulating GSTP1 (A) Effects of overexpression of STAT3 on SW620/shGSTP1 and HCT116/shGSTP1 cell invasion were detected by invasion assay. Scale bars represent 50  $\mu\text{m}$ . All samples were analyzed in triplicate. Bars represent the mean  $\pm$  SD. \* $P < 0.05$ , \*\* $P < 0.01$ . (B) Effects of overexpression of STAT3 on SW620/shGSTP1 and HCT116/shGSTP1 cell proliferation were detected by CCK8 assay. All samples were tested in triplicate. Bars represent the mean  $\pm$  SD. \* $P < 0.05$ , \*\* $P < 0.01$ .



**Figure 3**


Overexpression of GSTP1 can upregulate the expression of STAT3 in vivo (A) The expressions of GSTP1 and STAT3 in subcutaneous tumors of nude mice were detected by immunohistochemistry. Scale bars represent 50 µm (left) and 20 µm (right). (B) The expression of GSTP1 and STAT3 in orthotopic implantation of colorectal tumors and liver metastases in nude mice were detected by immunohistochemistry. Scale bars represent 50 µm (left) and 20 µm (right).






**Figure 4**

GSTP1 and STAT3 can interact with each other (A) The interaction between GSTP1 and STAT3 was detected by a co-immunoprecipitation assay with the SW620 cell line. (B) The co-location between GSTP1 and STAT3 was detected by an immunofluorescence assay with the SW620 cell line. Scale bars represent 10 μm. (C) The direct interaction site between GSTP1 and STAT3 was detected by a GST pull-down assay. (D) Western blot analysis was performed to detect the expression of JAK/STAT3 signaling pathway-related proteins in SW620/siGSTP1 and SW480/GSTP1 cell lines. (E) Western blot analysis was performed to detect the expression of JAK/STAT3 signaling pathway-related proteins in SW620/siSTAT3 and LoVo/STAT3 cell lines. (F) Western blot analysis was performed to detect the expression of GSTP1 and JAK/STAT3 signaling pathway-related proteins following AG490 treatment of LoVo cells.



**Figure 5**

The interaction between GSTP1 and STAT3 is regulated by FBX8 (A) The interaction between GSTP1 and STAT3 was detected by a CO-IP assay after AG490 treatment of SW620 cells. (B) The interaction between GSTP1 and STAT3 was detected by a CO-IP assay with SW480/FBX8 cells.



**Figure 6**

Schematic diagram of the role between GSTP1 and STAT3 in CRC

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Attachment1.pdf](#)